Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age3-39
SponsorNew York Medical College
About this trial
The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).
Eligibility criteria
Qualifiers
Adequate organ function
Disqualifiers
Primary mediastinal B-cell lymphoma (PMBL)
T-cell/histiocyte-rich large B-cell lymphoma
Gray zone lymphoma
Follicular lymphoma
Trial design
Treatments tested in this trial
- DOC Group B
- Pv-COMRAD 1 and 2 Group B
- Pv-R-CYM 1 and 2 Group B
- DOC Group C
- MAD CPR 1 and 2
- Pv-R CYVE 1 and 2
- Pv-R CYVE-MTX 1 and 2
- MAD CP
- Pv-Cytarabine/etoposide
- AD CP
- Bv-AVD-R 1 and 2: COHORT IIa
- Bv-NVD-R, Cycle 1-2
- Bv-NVD-R, Cycle 1-4 SER
- Bv-AVD-R
- Bv-NVD-R, Cycle 1-4 RER
- Bv-NAVD-R, Cycle 1-2
- Involved Site Radiation Therapy
Treatment groups
80 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov